FGFR3, fibroblast growth factor receptor 3, 2261

N. diseases: 654; N. variants: 55
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003864
Disease: Arthritis
Arthritis
0.010 Biomarker disease BEFREE Our study identifies the role of FGFR3 in synovial macrophage recruitment and synovitis, which provides a new insight into the pathological mechanisms of inflammation-related arthritis. 31662319 2020
CUI: C0021053
Disease: Immune System Diseases
Immune System Diseases
0.010 Biomarker group BEFREE Autoantibodies directed against TS-HDS and FGFR-3 suggest an immune disorder in otherwise idiopathic SFN. 31650561 2020
CUI: C0038436
Disease: Post-Traumatic Stress Disorder
Post-Traumatic Stress Disorder
0.010 Biomarker disease BEFREE Here, we investigated the potential of ACH-000029 to prevent anxiety-like behavior in the single prolonged stress (SPS) PTSD model. 31843397 2020
CUI: C0039103
Disease: Synovitis
Synovitis
0.010 Biomarker disease BEFREE Our study identifies the role of FGFR3 in synovial macrophage recruitment and synovitis, which provides a new insight into the pathological mechanisms of inflammation-related arthritis. 31662319 2020
CUI: C0151313
Disease: Sensory neuropathy
Sensory neuropathy
0.010 Biomarker disease BEFREE Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies. 31690697 2020
CUI: C3875321
Disease: Inflammatory dermatosis
Inflammatory dermatosis
0.010 Biomarker disease BEFREE However, the defect in the epidermal barrier and the resulting inflammatory skin disease that develops in mice lacking FGFR1 and FGFR2 in keratinocytes were further aggravated upon additional loss of FGFR3. 31830366 2020
Non-ST Elevated Myocardial Infarction
0.010 Biomarker disease BEFREE The aim of our study was to assess the frequency of coronary microvascular spasm in patients with NSTEMI without culprit lesion (MINOCA) by intracoronary acetylcholine testing (ACH-test). 31236694 2020
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.010 GeneticVariation disease BEFREE CAST‑PCR detected one FGFR3 mutation in 1/29 NBs. 31638167 2019
CUI: C0030246
Disease: Pustulosis of Palms and Soles
Pustulosis of Palms and Soles
0.010 Biomarker disease BEFREE The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. 30036598 2019
CUI: C0038525
Disease: Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
0.010 AlteredExpression disease BEFREE FGFR3 siRNA worsened neurobehavioral function and suppressed the expression of PI3k, p-Akt, and Bcl-2 rather than FGFR1 siRNA in SAH rats treated with rFGF-2. 31203572 2019
CUI: C0085138
Disease: Choroid Plexus Neoplasms
Choroid Plexus Neoplasms
0.010 AlteredExpression group BEFREE FGFR3 and FGFR1 proteins are expressed in a subpopulation of choroid plexus tumors. 31660579 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.010 AlteredExpression disease BEFREE FGFR3 expression in cutaneous malignant melanoma (CMM) tissues was positively correlated with the Breslow thickness and lymph node metastasis. 31619201 2019
CUI: C0263361
Disease: Psoriasis vulgaris
Psoriasis vulgaris
0.010 Biomarker disease BEFREE Psoriasis vulgaris concurrence was lowest in PPP (15.8% vs 54.4% in GPP and 46.2% in ACH, P < .0005 for both), whereas the mean age of onset was earliest in GPP (31.0 vs 43.7 years in PPP and 51.8 years in ACH, P < .0001 for both). 30036598 2019
CUI: C0343055
Disease: Generalized pustular psoriasis
Generalized pustular psoriasis
0.010 Biomarker disease BEFREE The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. 30036598 2019
Acrodermatitis continua of Hallopeau
0.010 Biomarker disease BEFREE The disease, which often manifests with concurrent psoriasis vulgaris, can have an acute systemic (generalized pustular psoriasis [GPP]) or chronic localized (palmoplantar pustulosis [PPP] and acrodermatitis continua of Hallopeau [ACH]) presentation. 30036598 2019
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.010 PosttranslationalModification disease BEFREE These results imply that the activity of the FGFR3 kinase in the infected epithelial cell restricts the HPV replication program through phosphorylation of E2 at Y138, which interferes with E2 binding to the Brd4 CTD, and that this interaction is required for initiation of viral DNA synthesis.<b>IMPORTANCE</b> Human papillomaviruses (HPVs) are highly infectious pathogens that commonly infect the oropharynx and uterine cervix. 30842331 2019
CUI: C0677932
Disease: Progressive Neoplastic Disease
Progressive Neoplastic Disease
0.010 Biomarker phenotype BEFREE Among patients with ACH, 25/28 (89.3%) had a complete response (CR), 2/28 (7.1%) had a partial response (PR) and 1/28 (3.6%) had a progressive disease (PD). 31074240 2019
CUI: C0687150
Disease: Parathyroid Gland Adenocarcinoma
Parathyroid Gland Adenocarcinoma
0.010 GeneticVariation disease BEFREE Nine PC samples (47%) harbored at least one potentially actionable genomic alteration including in the after genes: ROS1 (5/19; 26%), PTEN (3/19; 16%), TSC1 (2/19; 11%), PIK3CA (1/19; 5%), AKT1 (1/19; 5%), MTOR (1/19; 5%), ERBB2 (1/19; 5%), NTRK1 (1/19; 5%), IDH1 (1/19; 5%) and FGFR3 (1/19; 5%). 30362515 2019
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma
0.010 GeneticVariation disease BEFREE Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines. 31638167 2019
CUI: C3276706
Disease: Small Fiber Neuropathy
Small Fiber Neuropathy
0.010 GeneticVariation disease BEFREE Auto-antibodies targeting neuronal antigens trisulfated heparin disaccharide (TS-HDS) and fibroblast growth factor 3 (FGFR3) are found in up to 20% of patients with SFN. 31773305 2019
CUI: C3539781
Disease: Progressive cGVHD
Progressive cGVHD
0.010 Biomarker disease BEFREE Among patients with ACH, 25/28 (89.3%) had a complete response (CR), 2/28 (7.1%) had a partial response (PR) and 1/28 (3.6%) had a progressive disease (PD). 31074240 2019
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma
0.010 GeneticVariation disease BEFREE Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines. 31638167 2019
CUI: C0003467
Disease: Anxiety
Anxiety
0.010 Biomarker disease BEFREE Increased cholinergic signalling in hippocampus also increases behaviours related to anxiety and depression in mice, which can be reversed by ACh receptor antagonists. 28264149 2018
CUI: C0003469
Disease: Anxiety Disorders
Anxiety Disorders
0.010 Biomarker group BEFREE Increased cholinergic signalling in hippocampus also increases behaviours related to anxiety and depression in mice, which can be reversed by ACh receptor antagonists. 28264149 2018
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis
0.010 AlteredExpression disease BEFREE We further found that activated phospho-FGFR3 and -RSK2 were more highly observed in RA than in OA synovium. 29540697 2018